Literature DB >> 8296392

Adenosine receptor subtypes.

M G Collis1, S M Hourani.   

Abstract

The numerous and widespread effects of adenosine provide both an opportunity for the development of novel therapeutic agents acting via adenosine receptors and the challenge of achieving selectivity of action. The feasibility of achieving selectivity is enhanced if receptor subtypes can be identified. Biochemical, functional and receptor-cloning studies are beginning to provide convergent data supporting the existence of A1, A2A, A2B and A3 receptors. However, studies of the functional significance of these receptors in intact tissues both in vitro and in vivo have lagged behind the biochemical studies. In this article, Michael Collis and Susanna Hourani review the current status of adenosine receptor classification and propose that ligands with greater selectivity need to be evaluated in a wide range of functional preparations if the therapeutic potential of this area is to be realized.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8296392     DOI: 10.1016/0165-6147(93)90094-z

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  75 in total

1.  Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors.

Authors:  B K Kemp; T M Cocks
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  Acidosis-induced coronary constriction in the rat heart: evidence for the activation of L-type calcium channels.

Authors:  D A Wilson; B Woodward
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

3.  Effects of A1 and A2 adenosine receptor antagonists on the induction and reversal of long-term potentiation in guinea pig hippocampal slices of CA1 neurons.

Authors:  S Fujii; H Kato; K Ito; S Itoh; Y Yamazaki; H Sasaki; Y Kuroda
Journal:  Cell Mol Neurobiol       Date:  2000-06       Impact factor: 5.046

4.  Role of K+ channels in A2A adenosine receptor-mediated dilation of the pressurized renal arcuate artery.

Authors:  H M Prior; M S Yates; D J Beech
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

5.  A(₂A) adenosine receptor (A(₂A)AR) as a therapeutic target in diabetic retinopathy.

Authors:  Ahmed S Ibrahim; Mamdouh M El-Shishtawy; Wenbo Zhang; Ruth B Caldwell; Gregory I Liou
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

6.  Enhanced adenosine A(2B) mediated coronary response in reserpinised rat heart.

Authors:  Roselyn B Rose'Meyer; Glenn J Harrison; John P Headrick
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-14       Impact factor: 3.000

7.  Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor.

Authors:  Hua-Qing Liu; Wei-Yu Zhang; Xue-Ting Luo; Yang Ye; Xing-Zu Zhu
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

8.  Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO.

Authors:  P Nieri; E Martinotti; V Calderone; M C Breschi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

9.  Stimulation of human umbilical vein endothelial cell proliferation by A2-adenosine and beta 2-adrenoceptors.

Authors:  V Sexl; G Mancusi; S Baumgartner-Parzer; W Schütz; M Freissmuth
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 10.  Pharmacological rationale for the clinical use of caffeine.

Authors:  J Sawynok
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.